Amniotic fluid fluorescence polarisation values for assessing fetal lung maturation

M LEGGE, HC POTTER

From the Perinatal Biochemistry and Pathology Services, Christchurch Women's Hospital, Christchurch, New Zealand

SUMMARY The fluorescence probe 1,6, diphenyl-1,3,5-hexatriene was used to determine the microviscosity of third trimester amniotic fluid samples utilising an Aminco Bowman spectrofluorometer fitted with a polariser prism. The results were related to the lecithin sphingomyelin (L:S) ratio. A fluorescence polarisation value of 0.360 corresponded to an L:S ratio of 2:0 in uncomplicated and diabetic pregnancies. Pregnancies complicated by Rhesus disease gave significantly different fluorescence polarisation values when compared with the uncomplicated pregnancies.

The use of the lecithin to sphingomyelin ratio (L:S ratio) has proved invaluable in the prenatal assessment of fetal lung maturation, and has become an established technique in many laboratories. When the ratio of lecithin to sphingomyelin exceeds 2:0 there is minimal risk of the infant developing respiratory distress. Other tests for assessing fetal lung maturation have been introduced such as total phospholipids, free fatty acids, surface tension measurements and the stability of amniotic foam.

In 1971, Shinitzky et al. described a technique whereby the microviscosity of lipid systems could be determined using fluorescent probes. This was based on the principle that a lipid soluble fluorescent dye will preferentially absorb into phospholipid dispersions and is dependent upon the phospholipid acyl chain length, degree of saturation, and the concentration of lecithin to sphingomyelin. Subsequent work by Cogan et al. and Shinitzky and Barenholz demonstrated that the fluorescent probe 1,6, diphenyl-1,3,5-hexatriene (DPH) was of value in determining the microviscosity of phospholipid and phospholipid-cholesterol vesicles (liposomes). As amniotic fluid phospholipids are thought to exist as liposomes, and an empirical relation exists between liposomes, viscosity and surface tension, Shinitzky et al. investigated the use of DPH to assess fetal lung maturity. An inverse relation was demonstrated between increasing L:S ratio and the microviscosity of amniotic fluid. These findings led to the production of the Eliscant fetal lung maturity analyser, a dedicated instrument costing approximately $US 14 000.

In this report we have investigated the use of the DPH technique for assessing fetal lung maturation using a standard Aminco Bowman spectrofluorometer, fitted with a polarisation prism.

Material and methods

SAMPLES Amniotic fluid, free from meconium, was collected by transabdominal amniocentesis for fetal maturity assessment. In this series a total of 70 amniotic fluid samples, free from blood were tested. Of these, 50 were from uncomplicated pregnancies; 13 were from pregnancies complicated by Rhesus disease; and seven were from pregnancies complicated by maternal diabetes mellitus. In addition to these a further 10 moderately blood-stained amniotic fluid samples were tested. All samples were centrifuged immediately after collection and had an L:S ratio performed and quantified as described by Legge.

REAGENTS The fluorescent probe 1,6-diphenyl-1,3,5-hexatriene was purchased from Koch-Light Laboratories, Colnbrook, UK. Tetrahydrofuran (Fissons, AR), was used without further purification. The stock DPH solution was prepared by dissolving 5 mg of DPH in 10 ml of tetrahydrofuran. This may be stored in sealed ampoules at 4°C until required. A working solution of DPH is prepared by injecting 50 µl of stock DPH into 100 ml of vigorously stirred phosphate-buffered saline pH 7.4 at 25°C. A fresh DPH dispersion needs to be prepared daily.

METHOD Five hundred microlitres of centrifuged amniotic...
Amniotic fluid fluorescence polarisation values for assessing fetal lung maturation

1095

fluid is mixed with 2 ml of the DPH dispersion and incubated at 37°C for 30 min. After incubation the sample is allowed to cool to 24°C ± 1°C. The fluorescence polarisation is then read using a fluorometer with polarised excited light at 360 nm and emission 426 nm. It is not necessary to have the emission wavelength polarised. In this series an Aminco Bowman spectrofluorometer was used to which a Glan prism polariser (Aminco Bowman cat no A546-62140) had been fitted to the sample compartment. This can be easily performed by laboratory personnel.

Two adjustments are made to the polarisation prism. The first orientates the prism to pass only light polarised parallel to the direction of the excited light (designated \( I_{11} \)) and the second orientates the prism to pass only light perpendicular to the direction of polarisation of the excited light (designated \( I_{1} \)). The degree of fluorescence polarisation was then calculated using the formula shown below:

\[
\text{Fluorescence polarisation (P)} = \frac{I_{11} - I_{1}}{I_{11} + I_{1}}
\]

Results

An inverse relation was demonstrated between the L:S ratio and fluorescence polarisation (Figure). A Bravais-Pearson correlation coefficient of \(-0.763\) with a linear regression line of \( y = 0.4185 - 0.00295x \) and a standard error of estimate of \( y \) on \( x \) of 0.0259 was determined for the uncomplicated pregnancy group. Using the calculated regression line a fluorescence polarisation value of 0.360 corresponded to an L:S ratio of 2:0.

Fluorescence polarisation values from the pregnancies complicated by Rhesus disease, maternal diabetes mellitus and blood stained amniotic fluids were compared with uncomplicated pregnancies using the F test and t test for unpaired data. The Rhesus disease group demonstrated a significant difference in the fluorescence polarisation values, \( F = 2.69 \) (\( p < 0.05 \)). The L:S ratio in this group corresponded to a fluorescence polarisation value of 0.330. The maternal diabetes mellitus fluorescence polarisation values were not significantly different using both the F and t tests; \( F = 2.0, t = 1.1 \) (\( p > 0.05 \)). Similarly, no significant difference in fluorescence polarisation values was demonstrated with moderately blood-stained amniotic fluids using both the F and t tests, \( F = 1.23; t = 0.886 \) (\( p > 0.05 \)).

No infant born with a fluorescence polarisation value of 0.360 or less, in this series, developed respiratory distress syndrome.

Discussion

A method has been described which is well suited for the rapid assessment of fetal lung maturation, correlating well with fetal outcome and the L:S ratio. The close association of fluorescence polarisation and L:S ratio as described by Shinitzky et al.\(^{14}\) and other workers\(^{12,13}\) using dedicated instrumentation has been confirmed using a standard fluorometer fitted with a polariser. This should make the technique readily available to more laboratories who would not normally have the resources to purchase a dedicated analyser to determine fetal lung maturation. We can see no reason why this technique cannot be used on the simpler fluorometers providing suitable light source and filters are used.

As microviscosity relates to the total phospholipid, this technique is not a lecithin-specific method. However, as the major phospholipids present in third trimester are dipalmitoyl lecithin and phosphatidylglycerol,\(^{14}\) it follows that they would be the major contributors to the microviscosity of the amniotic fluid. Other phospholipids remain relatively constant.

At present no explanation can be given for the significant difference between fluorescence polarisation values for Rhesus disease pregnancies and uncomplicated pregnancies. This is being investigated further. Further investigations are also being conducted on the significance of amniotic fluid microviscosity and the relation of fetal phospholipid metabolism in complicated pregnancies.
This work was supported, in part, by a grant from the Medical Research Council of New Zealand.

References


Requests for reprints to: Dr M Legge, Department of Pathology, Christchurch Women’s Hospital, Christchurch, New Zealand.
Amniotic fluid fluorescence polarisation values for assessing fetal lung maturation.
M Legge and H C Potter

doi: 10.1136/jcp.34.10.1094

Updated information and services can be found at:
http://jcp.bmj.com/content/34/10/1094

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/